Tykerb (Breast cancer) Analysis and Forecasts to 2020


#28325

49pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Tykerb (Breast cancer) - Analysis and Forecasts to 2020 provides Tykerb sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Tykerb including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Tykerb including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts from 2007-2020 for Tykerb in the seven major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Analysis and Forecasts Report Guidance 7


3 Breast Cancer: Market Characterization 9
3.1 Breast Cancer Market 9
3.2 Breast Cancer Market Forecasts and CAGR 9
3.3 Drivers of Breast Cancer Market 10
3.3.1 High Prevalence 10
3.3.2 Breast Cancer: Most Frequent Cancer in Women 10
3.3.3 Increasing Breast Cancer Incidence Rate 11
3.3.4 Decreasing Breast Cancer Mortality Rate 13
3.3.5 High Survival Rates of Breast Cancer 15


4 Staging of Breast Cancer: Introduction 16
4.1 Distribution of Patients by Stages 16
4.1.1 Stages 16


5 Predictive Biomarker in the Treatment of Breast Cancer 19


6 Treatment Options of Breast Cancer 21
6.1 Stage 0 Breast Cancer: Treatment Options 21
6.2 Early Stage Breast Cancer (Excluding Stage 0) 22
6.3 Metastatic Breast Cancer (MBC) 24
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 24
6.3.2 Cytotoxic Chemotherapy 26
6.3.3 Management of Patients with HER-2 Positive Patients 29


7 Tykerb 31
7.1 Introduction 31
7.2 Mechanism of Action 31
7.3 Clinical Studies 31
7.4 Approval History of Tykerb 32
7.5 Factors Affecting Sales of Tykerb 32
7.5.1 Breast Cancer Market 32
7.5.2 Tykerbs Potential Benefits 32
7.5.3 Usage in Many Stages and Lines of Breast Cancer 32
7.5.4 Favourable Toxicity Profile 32
7.6 Drug Evaluation 32
7.6.1 Drug Risk Benefit Score 32
7.6.2 Intensity of Competition 33
7.7 Sales Forecast of Tykerb 34
7.7.1 Target Patient Pool of Tykerb 34
7.7.2 Dosing 35
7.7.3 Market Penetration 35
7.7.4 Annual Cost of Therapy 35
7.7.5 Sales Projections of Tykerb 36


8 Breast Cancer Market: Appendix 45
8.1 Market Definitions 45
8.2 Abberiviations 45
8.3 Research Methodology 45
8.3.1 Coverage 45
8.3.2 Secondary Research 46
8.3.3 Forecasting 46
8.3.4 Number of Patients Approved to take the Drug 46
8.3.5 Net Penetration of Drug 47
8.3.6 Net Annual Dosing 48
8.3.7 Annual Cost of Therapy 48
8.3.8 Primary Research 48
8.3.9 Expert Panels 49
8.4 Contact Us 49
8.5 Disclaimer 49
8.6 Sources 49


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 9
Table 3: Five-Year Relative Survival Rates, By Stages 15
Table 4: Tykerb Approval History 32
Table 5: Drug Risk Benefit Score (DRB) of Tykerb 33
Table 6: Tykerb, Breast Cancer, Global, Sales Forecasts ($m), 20072020 36
Table 7: Tykerb, Breast Cancer, The US, Sales Forecasts ($m), 20072020 37
Table 8: Tykerb, Breast Cancer, The UK, Sales Forecasts ($m), 20082020 38
Table 9: Tykerb, Breast Cancer, France, Sales Forecasts ($m), 20082020 39
Table 10: Tykerb, Breast Cancer, Germany, Sales Forecasts ($m), 20082020 40
Table 11: Tykerb, Breast Cancer, Italy, Sales Forecasts ($m), 20082020 41
Table 12: Tykerb, Breast Cancer, Spain, Sales Forecasts ($m), 20082020 42
Table 13: Tykerb, Breast Cancer, Japan, Sales Forecasts ($m), 20082020 43


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Global, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 9
Figure 3: Top Ten Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 10
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 12
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 12
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 13
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 13
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 14
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 14
Figure 12: Broad Classification of Breast Cancer, By Type 16
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 16
Figure 14: Classification of Invasive Breast Cancer, By Stages 17
Figure 15: Classification of Invasive Breast Cancer, By Treatment 17
Figure 16: Classification of Metastatic or Advanced Breast Cancer 17
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 18
Figure 18: Classification of Locally Advanced Breast Cancer 18
Figure 19: Metastatic Breast Cancer Classification 18
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 19
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 20
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 20
Figure 23: Treatment Options, DCIS Breast Cancer 21
Figure 24: Treatment Options, LCIS Breast Cancer 22
Figure 25: Treatment Options, Stages I, II and IIIA 22
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 23
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 23
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 24
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 25
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 26
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 28
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 29
Figure 33: Drug Model Diagram of Tykerb 34
Figure 34: Tykerb, Breast Cancer, Global, Sales Forecasts ($m), 20072020 36
Figure 35: Tykerb, Breast Cancer, The US, Sales Forecasts ($m), 20072020 37
Figure 36: Tykerb, Breast Cancer, The UK, Sales Forecasts ($m), 20082020 38
Figure 37: Tykerb, Breast Cancer, France, Sales Forecasts ($m), 20082020 39
Figure 38: Tykerb, Breast Cancer, Germany, Sales Forecasts ($m), 20082020 40
Figure 39: Tykerb, Breast Cancer, Italy, Sales Forecasts ($m), 20082020 41
Figure 40: Tykerb, Breast Cancer, Spain, Sales Forecasts ($m), 20082020 42
Figure 41: Tykerb, Breast Cancer, Japan, Sales Forecasts ($m), 20082020 43
Figure 42: Tykerb, Breast Cancer, Global, Sales Distribution by country ($bn), 2020 44
Figure 43: Drug Model Diagram 47
Figure 44: Patients Approved for the Drug 48